Equitec Proprietary Markets’s Trillium Therapeutics Inc. TRIL Stock Holding History

Equitec Proprietary Markets’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-126,597	Closed	-$2.22M	–	499
2021 Q3	$2.22M	Buy	+126,597	New	+$1.48M	0.41%	37

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Equitec Proprietary Markets's TRIL Position: Q4 2021 in Review

Equitec Proprietary Markets sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 126,597 shares — an estimated $2.22M sold.

Equitec Proprietary Markets first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $2.22M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Equitec Proprietary Markets reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Equitec Proprietary Markets sold 126,597 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.22M.
Equitec Proprietary Markets first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Equitec Proprietary Markets's Trillium Therapeutics Inc. position peaked at $2.22M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Equitec Proprietary Markets's 13F filing for Q4 2021, filed 31 Jan 2022.